SARS-CoV-2 - Azithromycin - Therapeutic Candidates

SARS-CoV-2 - Azithromycin - Therapeutic Candidates


Azithromycin is a macrolide antibiotic. This broad-spectrum antibiotic of the azalide group is a derivative of erythromycin. Azithromycin is indicated for the treatment of certain types of mild to moderate infections caused by bacteria. Most commonly, it is used to treat ear infections such as otitis media, throat and lung infections such as pharyngitis and pneumonia, and certain skin infections. Azithromycin is also prescribed to patients with cystic fibrosis because they are particularly susceptible to respiratory infections.
A recent study, in the context of the Covid-19 epidemic currently affecting many countries around the world, sought to investigate the effect of azithromycin in combination with hydroxychloroquine. The interest in azithromycin came from the fact that the rate of Covid-19 infection was low in a large cohort of patients with cystic fibrosis, many of whom are on azithromycin therapy.

Resultado da sua pesquisa : 276 produto encontrado

Refine sua procura :

RUOCE / IVD
  • Unconjugated 38
  • Biochemicals 230
  • Inhibitor/Antagonist/Agonist 42
  • Buffers and reagents 2
  • cell culture products 2
  • Assay 3
  • Cell culture 2
APLICAR OS FILTROS
REINICIALIZAR


Referência
Descrição
Cond.
Price Bef. VAT
331-20216-2
 25mg 
331-20216-1
 10mM(in1mLDMSO) 
331-20216-3
 50mg 
407380-2.5mg
 2.5mg 
407380-1mg
 1mg 
AG003NY3-1g
 1g 
M5438-50mg
 50mg 
CV-1101-1
 25.0mg 
M5438-100mg
 100mg 
AG003NY3-5g
 5g 
440470-2.5mg
 2.5mg 
440470-1mg
 1mg 
TRC-O847180-1MG
 1mg 
TRC-O847180-2.5MG
 2.5mg 
TRC-O847180-5MG
 5mg 
257209-250mg
 250mg 
257209-25mg
 25mg 
162716-100mg
 100mg